Navigation Links
Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target

New study demonstrates 75% of patients receiving highest dose achieves A1c with no associated hypoglycemia

CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- According to findings presented today at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois, the investigational treatment liraglutide, a once- daily dose of human GLP-1 analog under development by Novo Nordisk for the treatment of type 2 diabetes significantly improved glycemic control (A1c) by reducing both fasting and post-meal glucose levels in people with type 2 diabetes. The Phase 2 study included 226 Japanese patients with type 2 diabetes treated over a period of 14 weeks. Results showed that liraglutide was effective and well tolerated within a wide dose range, allowing nearly 75 percent of patients receiving the highest dose to achieve glycemic control (A1c<7.0%) without hypoglycemia.(1)

"One challenge with insulin and many oral antidiabetic agents, which boost insulin secretion or heighten insulin sensitivity, is that they can lower blood glucose levels, resulting in hypoglycemia, which can sometimes be dangerous," said Professor Yutaka Seino, Director of Kansai-Denryoku Hospital and professor, Department of Metabolism & Clinical Nutrition, Graduate School of Medicine, Kyoto University, and lead investigator on the trial. "A well- tolerated agent with once-daily administration that can allow a majority of patients to achieve good glycemic control with a low risk of hypoglycemia and no weight gain is very promising and will be a considerable advance in diabetes treatment."

Liraglutide acts to lower blood glucose when levels are elevated, and previous studies have shown it is associated with a low risk of hypoglycemia.(2)(3)

About the Study (Abstract #0520-P)

In the study, 226 Japanese type 2 diabetes patients treated with diet or a single oral anti-diabetic drug, discontinued
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014   ... of advanced cancer genome analysis and testing services, ... discovering and developing highly selective kinase inhibitors for ... genomic study of malignant mixed Mullerian tumors (MMMT), ... reproductive system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/20/2014)... The excitement is building up once again for the annual ... year the Surry Arts Council will be celebrating its 25th year ... are still fans of the Andy Griffith Show. ... CBS from 1960 through 1968. The show ranked by TV ... Mount Airy, North Carolina is where the show was filmed calling ...
(Date:9/20/2014)... September 20, 2014 Plumbing construction ... out of 5, indicating a moderately favorable purchasing environment ... score reflects current and future pricing trends that will ... prices. Other factors that negatively affect buyer power are ... construction and the moderate switching costs. Buyers benefit, however, ...
(Date:9/20/2014)... 2014 Final Cut Pro X Plugin ... of the Information theme for FCPX filmmakers. , “Fun, cool, ... the Information theme,” says Christina Austin, CEO of Pixel Film ... professional.” , Information features easy to use controls that give ... environment. Change the background color, color of each circle outline, ...
(Date:9/20/2014)... 20, 2014 MarijuanaDoctors.com recently returned ... at the PAIN Week conference that was held ... Casino in Las Vegas from September 2nd to ... PAIN Week in the hopes of educating physicians ... and legitimate tool to treat chronic Pain, MarijuanaDoctors.com ...
(Date:9/19/2014)... September 19, 2014 “Copay coupons,” a ... of brand drugs among patients with prescription drug coverage, ... to a new report from the Department of ... (OIG). Federal anti-kickback laws prohibit suppliers from offering side-payments ... the federal government. , The report highlights that two ...
Breaking Medicine News(10 mins):Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2
... well-proven medications, could have huge impact, expert says , ... of a statin and a blood pressure-lowering ACE inhibitor ... or stroke reduced their incidence by more than 60 ... the study all had diabetes or a history of ...
... BNVI ) today announced that it has entered into agreements ... price per unit of $6.20 for aggregate gross proceeds of up ... common stock and ten warrants. Each warrant entitles its holder ... price of $0.85. The warrants may be exercised at any ...
... Anterior cruciate ligament (ACL) injuries are one of the ... of patients undergo reconstructive surgery to repair these injuries. ... issue of The Journal of Bone and Joint Surgery ... increasing substantially and women and younger patients are more likely ...
... have demonstrated that a protein called NEDD9 may be required ... to grow. Their findings, based on the study of a ... issue of Cancer Research , available on-line now. ... evidence that directly demonstrates reduced levels of NEDD9 in a ...
... No clear evidence found that Chantix has dangerous side ... News) -- The smoking cessation drug varenicline (Chantix) does ... to a new British study. , In July, the ... carry a "black-box warning" on its packaging, indicating that ...
... iMobile® Care ... ... information to provide essential and practical aid and care during serious situations is crucial and ... able to deliver a timely response, or to administer self-care without a costly physician or ...
Cached Medicine News:Health News:Drug Combo May Prevent Heart Attacks, Strokes 2Health News:Drug Combo May Prevent Heart Attacks, Strokes 3Health News:Bionovo Announces Pricing of Securities Offering 2Health News:Bionovo Announces Pricing of Securities Offering 3Health News:Teenagers and ACL: Tears common and additional surgery likely 2Health News:NEDD9 protein supports growth of aggressive breast cancer 2Health News:Study Counters Warnings on Quit-Smoking Drug 2Health News:VisionSync Launches a Smart iPhone First Aid App, iMobile Care 2Health News:VisionSync Launches a Smart iPhone First Aid App, iMobile Care 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: